Latest Healthcare Research Reports

Tag: neurodegenerative disorder therapeutics market overview

Leqembi Market Expected To Grow At % CAGR Through 2030: What Businesses Need To Know

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Leqembi Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

Historical growth can be linked to the rising occurrence of Alzheimer’s disease, progress in monoclonal antibody research, heightened recognition of the value of early diagnosis, the broadening of neurology specialty care services, and regulatory clearances for specific treatments.

The anticipated growth during the projection period stems from greater financial commitment to neurodegenerative disease studies, a wider uptake of early diagnostic instruments, the broadening of personalized Alzheimer’s care strategies, a heightened emphasis on delaying disease advancement, and expanded insurance coverage for novel treatments. Concurrently, key trends expected over the forecast horizon encompass the increasing integration of amyloid-targeting treatments, a heightened concentration on interventions for early-stage Alzheimer’s, an escalating need for disease-modifying neurodegenerative treatments, the broadened application of biomarker-informed patient selection, and improved assessment of cognitive results.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=40198118&type=smp&name=Leqembi%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leqembi Market Growth Backed By Core Demand Fundamentals

The rising incidence of Alzheimer’s disease is significantly influencing the leqembi market. Alzheimer’s disease is a neurodegenerative condition that progressively impairs memory, cognitive abilities, and behavior, interfering with daily activities. Its development is multifaceted, involving genetic, lifestyle, and environmental elements. Leqembi works by decreasing beta-amyloid plaques in the brain, thereby helping to slow cognitive deterioration in the early stages of Alzheimer’s disease by targeting these plaques and safeguarding memory and cognitive functions. For example, the European Brain Council, a Belgium-based international health organization, reported in September 2024 that approximately 7 million individuals in Europe currently live with Alzheimer’s disease, a figure projected to double to 14 million by 2030 due to an aging population, making it a critical global public health concern. Consequently, the growing prevalence of Alzheimer’s disease is a key driver for the leqembi market’s expansion.

Leqembi Market Driver: Advancements In Intravenous Maintenance Dosing For Alzheimer’s Treatment

Leqembi Market Segment Outlook: Which Categories Are Growing Fastest?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Leqembi Market Leading Companies And Competitive Benchmarking

Major companies operating in the leqembi market are Eisai Co. Ltd.

View The Full Leqembi Market Report:

https://thebusinessresearchcompany.com/report/leqembi-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Leqembi Market Regional Analysis And Top Geography

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 16, 2026
Neurodegenerative Disorder Therapeutics Market Size Reaches $23.65 Billion In 2026: What Is Driving Growth?

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Neurodegenerative Disorder Therapeutics Market Revenue Growth On Track For A 9.6% CAGR Through 2030

The neurodegenerative disorder therapeutics market has shown substantial growth over the past few years. This market is expected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. The rise observed in previous periods is attributable to the increasing incidence of neurodegenerative diseases, an expanding elderly population, restricted availability of treatment options, enhanced awareness for prompt diagnosis, and improvements in hospital and neurology care facilities.

The neurodegenerative disorder therapeutics market is projected to experience substantial expansion over the coming years, reaching $34.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is fueled by several factors, including the progress in gene therapies, improvements in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring systems, increased funding for clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Key trends expected during this period involve the wider acceptance of neuroprotective and neurorestorative treatments, an increased emphasis on managing symptoms and providing patient-centered care, a rise in clinical trials for new neurodegenerative medications, the proliferation of personalized and targeted therapeutic methods, and the merging of home care with remote monitoring solutions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=35759531&type=smp&name=Neurodegenerative%20Disorder%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurodegenerative Disorder Therapeutics Market Growth Catalysts And Demand Drivers

Increased investment in research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to drive the expansion of the neurodegenerative disorder therapeutics market moving forward. Governments and organizations are undertaking these R&D investments for neurodegenerative disorders due to various persuasive reasons, such as rising prevalence, significant unaddressed medical requirements, economic ramifications, and global health initiatives. For instance, in March 2023, the Government of Canada, a federal administration based in Canada, announced a $38.3 million investment in 2023 aimed at advancing research into neurodegenerative diseases. Therefore, a continued increase in research and development (R&D) investment for neurodegenerative disorder therapeutics will fuel the growth of the neurodegenerative disorder therapeutics market during the forecast period.

Neurodegenerative Disorder Therapeutics Market Segmentation: How Does The Market Break Down By Category?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Neurodegenerative Disorder Therapeutics Market Trends Shaping Long-Term Demand

Leading companies within the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, such as prodrug formulations, to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that the body metabolically converts into active drugs, enabling a controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Neurodegenerative Disorder Therapeutics Market Competitive Overview And Top Companies

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

View The Full Neurodegenerative Disorder Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Neurodegenerative Disorder Therapeutics Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

October 13, 2026
Leqembi Market Outlook Highlights The Next Major Growth Opportunities

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Leqembi Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The upward trend observed during the historical timeframe resulted from a rising frequency of Alzheimer’s disease cases, progress made in monoclonal antibody studies, heightened recognition of the value of early detection, the broadening of specialized neurology services, and official authorizations granted for specific treatments.

The anticipated growth during the forecast period is driven by heightened funding into neurodegenerative disease studies, a greater embrace of early detection technologies, broader implementation of customized Alzheimer’s care plans, an intensified emphasis on decelerating disease advancement, and expanded insurance support for novel treatments. Key developments shaping this period involve the growing utilization of therapies aimed at amyloid proteins, a stronger concentration on addressing Alzheimer’s in its initial phases, rising requests for interventions that modify the course of neurodegenerative conditions, wider application of biomarker-based patient identification, and more thorough assessment of cognitive performance.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Leqembi Market Demand Drivers: What Is Fueling Industry Growth?

The rising incidence of Alzheimer’s disease is becoming an increasingly significant factor in the leqembi market moving forward. Alzheimer’s disease is a degenerative neurological disorder that progressively impairs memory, thinking, and behavior, disrupting everyday activities. This condition is multifaceted, with various elements influencing its onset, such as genetic predispositions, lifestyle choices, and environmental factors. By reducing beta-amyloid plaques in the brain, Leqembi helps slow cognitive deterioration in early-stage Alzheimer’s, targeting these plaques to preserve memory and cognitive abilities. As an example, in September 2024, data from the European Brain Council, a health organization based in Belgium, revealed that around 7 million individuals in Europe are currently affected by Alzheimer’s disease. This figure is anticipated to double to 14 million by 2030, driven by an aging population, highlighting it as a major global public health issue. Consequently, the growing prevalence of Alzheimer’s disease is fueling expansion of the leqembi market.

Leading companies within the leqembi market are concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to decrease how often administration is needed for Alzheimer’s patients. An intravenous maintenance dosing formulation involves infusing a steady or repeated medication dose directly into the bloodstream to preserve therapeutic levels over an extended timeframe. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical company from Japan, together with Biogen Inc., a biotechnology firm based in the US, reported that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous maintenance dosing schedule. This approach targets harmful amyloid proteins, especially protofibrils, which are thought to drive cognitive decline in Alzheimer’s disease. LEQEMBI has demonstrated clinical and biomarker advantages in prolonging treatment effectiveness, potentially lessening neuronal harm, and enhancing long-term patient results.

Leqembi Market Segmentation And Category Breakdown

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Leqembi Market Competitive Analysis Of Major Industry Participants

Major companies operating in the leqembi market are Eisai Co. Ltd.

Access The Complete Leqembi Market Report:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Leqembi Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 10, 2026
Neurodegenerative Disorder Therapeutics Market Growth Through 2030 Creates New Strategic Opportunities

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Neurodegenerative Disorder Therapeutics Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for therapeutics targeting neurodegenerative disorders has experienced robust expansion over the past several years. It is projected to rise from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical growth was driven by factors such as the increasing incidence of neurodegenerative conditions, a growing elderly demographic, insufficient therapeutic alternatives, heightened awareness surrounding early detection, and the ongoing development of hospital and neurology care facilities.

The neurodegenerative disorder therapeutics market is projected to experience robust expansion over the coming years, with an anticipated rise to $34.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.6%. This forecast period growth is driven by several key developments, including the emergence of gene therapies, progress in monoclonal antibody-based treatments, the incorporation of artificial intelligence-powered diagnostic and monitoring tools, increased funding for clinical research and trials, and the broadening of personalized medicine and targeted therapeutics. Among the prominent trends shaping this period are a growing utilization of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an expansion of clinical trial activities focused on novel neurodegenerative drugs, a further advancement of personalized and targeted therapeutic strategies, and the integration of home care solutions with remote monitoring technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neurodegenerative Disorder Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?

The anticipated rise in funding directed toward research and development (R&D) for treatments of neurodegenerative disorders is set to fuel expansion within the neurodegenerative disorder therapeutics market moving forward. Such investments are initiated by governments and organizations for several strong reasons, including the growing frequency of these conditions, substantial gaps in existing medical care, associated economic burdens, and worldwide health priorities. As an example, in March 2023, the Government of Canada, a federal entity based in Canada, disclosed a $38.3 million commitment to support research on neurodegenerative diseases. Consequently, this sustained increase in R&D investment for neurodegenerative disorder therapies will keep driving market growth throughout the forecast period.

Neurodegenerative Disorder Therapeutics Market Segment Breakdown: Which Categories Generate The Most Revenue?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Neurodegenerative Disorder Therapeutics Market Trends: What Is Shaping Future Industry Growth?

Key players in the neurodegenerative disorder therapeutics market are placing increased emphasis on creating novel treatment strategies, including prodrug formulations, designed to boost the bioavailability, effectiveness, and safety profile of therapies for Parkinson’s disease. Prodrugs, which are biologically inactive substances that undergo metabolic conversion into their active pharmacological forms within the body, enable a regulated and prolonged release of active pharmaceutical ingredients. A notable example occurred in January 2024, when AbbVie Inc., a biopharmaceutical firm based in the United States, introduced PRODUODOPA (foslevodopa or foscarbidopa) across the European Union for individuals suffering from advanced Parkinson’s disease. This approach uses a soluble prodrug combination to ensure continuous levodopa administration, with the goal of minimizing motor fluctuations and enhancing patients’ overall quality of life. By providing an alternative to conventional intermittent oral dosing and supporting better adherence to treatment, this product launch marks a crucial step forward in the management of advanced Parkinson’s disease.

Neurodegenerative Disorder Therapeutics Market Key Players And Strategic Industry Positioning

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Neurodegenerative Disorder Therapeutics Market Largest Region By Revenue And Market Share

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 6, 2026
Leqembi Market Industry Outlook 2026–2030 Highlighting Growth Momentum And Market Trends

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Leqembi Market Between 2026 And 2030?

The growth observed in the historical period was primarily influenced by the escalating prevalence of Alzheimer’s disease. This was further supported by advancements in monoclonal antibody research, an increased understanding of the importance of early diagnosis, the expansion of specialty neurological care, and the securing of regulatory approvals for targeted therapies.

Anticipated growth in the forecast period is primarily attributed to heightened investment in neurodegenerative disease research, the increasing utilization of early diagnostic instruments, the expansion of personalized Alzheimer’s treatment protocols, a growing emphasis on decelerating disease progression, and enhanced payer coverage for innovative therapies.

Significant trends expected during the forecast period involve the increasing integration of amyloid-targeting therapies, a rising focus on early-stage Alzheimer’s intervention, an escalating demand for disease-modifying neurodegenerative treatments, the expanded application of biomarker-guided patient selection, and improved monitoring of cognitive outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

Which Core Factors Are Supporting The Expansion Of The Leqembi Market?

The growing occurrence of Alzheimer’s disease is becoming a significant factor in the leqembi market. Alzheimer’s disease, a progressive brain condition, impairs memory, cognition, and behavior, severely affecting daily activities. This intricate disorder results from a combination of genetic, lifestyle, and environmental elements. Leqembi functions by diminishing beta-amyloid plaques in the brain, thereby slowing the progression of cognitive decline in early Alzheimer’s by targeting these plaques and safeguarding memory and other cognitive functions. For example, as reported in September 2024 by the European Brain Council, an international health organization located in Belgium, about 7 million individuals in Europe currently suffer from Alzheimer’s disease; this figure is projected to reach 14 million by 2030 due to an aging population, presenting a major global public health concern. Consequently, the increasing prevalence of Alzheimer’s disease is fueling the expansion of the leqembi market. Companies prominent in the leqembi market are concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to lessen the frequency of drug administration for those with Alzheimer’s disease. An IV maintenance dosing formulation entails administering a regular or repeated dose of medicine straight into the bloodstream to maintain therapeutic concentrations over an extended period. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical firm based in Japan, and Biogen Inc., a US-based biotechnology company, reported that the U.S. Food and Drug Administration (FDA) had granted acceptance to a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing schedule. This therapy aims at harmful amyloid proteins, particularly protofibrils, which are thought to contribute to cognitive decline in Alzheimer’s disease (AD). LEQEMBI has demonstrated advantages in clinical trials and biomarkers, prolonging treatment effectiveness, possibly decreasing neuronal damage, and enhancing patient results over the long term.

How Is Segment Classification Applied In The Leqembi Market?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Who Are The Companies Shaping The Leqembi Market Landscape?

Major companies operating in the leqembi market are Eisai Co. Ltd.

Access The Complete Leqembi Market Report:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

What Is The Largest Regional Market In The Leqembi Market?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 25, 2026
Elevated R&D Investments Driving Growth In The Neurodegenerative Disorder Therapeutics Market Is Supporting Development Across The Neurodegenerative Disorder Therapeutics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Neurodegenerative Disorder Therapeutics Market Compare Between 2026 And 2030?

The neurodegenerative disorder therapeutics market size has seen strong growth in recent years. It is anticipated to increase from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. The expansion observed in previous periods can be linked to the rising prevalence of neurodegenerative conditions, an expanding aging population, limited therapeutic options, increased awareness surrounding early diagnosis, and the development of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is expected to show significant growth in the upcoming period. It is forecast to grow to $34.13 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. This expansion over the forecast period is driven by factors such as the development of gene therapies, advances in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, a rise in investment for clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Notable trends during this time include the increasing adoption of neuroprotective and neurorestorative therapies, a growing emphasis on symptom management and patient-centric care, an increase in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the integration of home care and remote monitoring solutions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

Which Major Factors Are Contributing To The Development Of The Neurodegenerative Disorder Therapeutics Market?

Growing spending on research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to boost the expansion of the neurodegenerative disorder therapeutics market. Governments and various organizations initiate R&D investments in neurodegenerative disorders due to several crucial factors, such as the rising incidence, considerable unmet patient needs, economic consequences, and global health objectives. For example, in March 2023, the Government of Canada, a federal administration, disclosed an investment of $38.3 million to advance research in neurodegenerative diseases. Consequently, continued investment in R&D for neurodegenerative disorder therapeutics is expected to fuel the market’s expansion in the foreseeable future.

How Is The Neurodegenerative Disorder Therapeutics Market Distributed Across Key Segments?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

Which Trends Are Influencing The Expansion Of The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are directing their efforts towards developing innovative treatment options, such as prodrug formulations, to improve the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs within the body, facilitating controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and enhance patients’ quality of life. This launch signifies a substantial advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.

Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Access The Complete Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Area Represents The Largest Portion Of The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurodegenerative Disorder Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 20, 2026
The Rise Of Advanced Skin-Strengthening Ampoules Deliver High Potency Active Ingredients Is Influencing The Leqembi Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Leqembi Market Be By 2030 Compared To Its 2026 Market Size?

The historical expansion was propelled by an escalation in the prevalence of Alzheimer’s disease, significant strides in monoclonal antibody research, an increased understanding of the criticality of early diagnosis, the broadening of neurology specialty care provisions, and the obtaining of regulatory clearances for specific therapies.

The anticipated growth during the forecast period stems from escalating investments in neurodegenerative disease research, broader integration of early diagnostic tools, the evolution of personalized Alzheimer’s treatment approaches, an increased commitment to decelerating disease progression, and expanded payer coverage for novel therapies.

Significant trends expected in the forecast period encompass a growing uptake of amyloid-targeting treatments, a heightened focus on early-stage Alzheimer’s intervention, a rising demand for disease-modifying neurodegenerative therapies, the expanded application of biomarker-guided patient selection, and more robust monitoring of cognitive outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

Which Primary Drivers Are Impacting The Leqembi Market Growth?

The growing occurrence of Alzheimer’s disease is becoming a significant factor in the leqembi market. Alzheimer’s disease, a progressive brain condition, impairs memory, cognition, and behavior, severely affecting daily activities. This intricate disorder results from a combination of genetic, lifestyle, and environmental elements. Leqembi functions by diminishing beta-amyloid plaques in the brain, thereby slowing the progression of cognitive decline in early Alzheimer’s by targeting these plaques and safeguarding memory and other cognitive functions. For example, as reported in September 2024 by the European Brain Council, an international health organization located in Belgium, about 7 million individuals in Europe currently suffer from Alzheimer’s disease; this figure is projected to reach 14 million by 2030 due to an aging population, presenting a major global public health concern. Consequently, the increasing prevalence of Alzheimer’s disease is fueling the expansion of the leqembi market. Companies prominent in the leqembi market are concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to lessen the frequency of drug administration for those with Alzheimer’s disease. An IV maintenance dosing formulation entails administering a regular or repeated dose of medicine straight into the bloodstream to maintain therapeutic concentrations over an extended period. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical firm based in Japan, and Biogen Inc., a US-based biotechnology company, reported that the U.S. Food and Drug Administration (FDA) had granted acceptance to a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing schedule. This therapy aims at harmful amyloid proteins, particularly protofibrils, which are thought to contribute to cognitive decline in Alzheimer’s disease (AD). LEQEMBI has demonstrated advantages in clinical trials and biomarkers, prolonging treatment effectiveness, possibly decreasing neuronal damage, and enhancing patient results over the long term.

How Is The Leqembi Market Segmented Across Different Segment Categories?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Which Organizations Play A Role In The Leqembi Market Landscape?

Major companies operating in the leqembi market are Eisai Co. Ltd.

Get The Full Leqembi Market Report:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Region Has The Greatest Market Share In The Leqembi Market?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Leqembi Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Browse Through More Reports Similar to the Global Leqembi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 5, 2026
Rising Prevalence Of Chronic Pain Conditions Fueling The Growth Of The Due To Increasing Demand For Targeted Long-Term Pain Management Is Contributing To Changes In The Neurodegenerative Disorder Therapeutics Market

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Neurodegenerative Disorder Therapeutics Market Expected To Change From 2026 To 2030?

The market for neurodegenerative disorder therapeutics has witnessed substantial expansion in recent years. Its value is set to increase from $21.66 billion in 2025 to $23.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The previous period’s growth can be attributed to several factors including the rising incidence of neurodegenerative conditions, an expanding aging population, the limited array of available treatments, increasing public understanding of the benefits of early diagnosis, and the improvement of hospital and neurological care infrastructure.

The neurodegenerative disorder therapeutics market is expected to experience significant growth over the next few years, with its size projected to reach $34.13 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This expansion during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the incorporation of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the broader application of personalized medicine and targeted therapeutics. Significant trends for this period encompass the growing adoption of neuroprotective and neurorestorative therapies, a heightened emphasis on symptom management and patient-centric care, an increase in clinical trials for innovative neurodegenerative drugs, the wider use of personalized and targeted therapeutic methods, and the integration of home care and remote monitoring solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp

What Key Drivers Are Fueling The Growth Of The Neurodegenerative Disorder Therapeutics Market?

Rising financial allocation towards research and development (R&D) in the field of neurodegenerative disorder therapeutics is projected to fuel the expansion of the neurodegenerative disorder therapeutics market moving ahead. Funding for research and development concerning neurodegenerative disorders is initiated by governmental bodies and organizations due to several strong factors, such as the growing incidence, substantial unaddressed medical requirements, financial implications, worldwide health endeavors, among others. As an illustration, in March 2023, the Government of Canada, a Canada-based federal administration, announced in 2023 a financial commitment of $38.3 million dedicated to furthering research into neurodegenerative diseases. Consequently, an escalating commitment to research and development (R&D) for neurodegenerative disorder therapeutics is anticipated to consistently propel the expansion of the neurodegenerative disorder therapeutics market throughout the projected timeframe.

How Is The Neurodegenerative Disorder Therapeutics Market Organized By Segment Classification?

The neurodegenerative disorder therapeutics market covered in this report is segmented –

1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types

2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types

3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics

2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies

3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids

4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications

5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

What Trends Are Affecting The Direction Of The Neurodegenerative Disorder Therapeutics Market?

Leading companies in the neurodegenerative disorder therapeutics market are concentrating on creating innovative treatment options, such as prodrug formulations, to enhance the bioavailability, effectiveness, and safety profiles of Parkinson’s disease therapies. Prodrugs are inert compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy leverages a soluble prodrug combination to ensure continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. The launch signifies a considerable advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and enhancing treatment adherence.

Who Are The Industry Participants Involved In The Neurodegenerative Disorder Therapeutics Market?

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

Get The Full Neurodegenerative Disorder Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Which Region Is The Largest In The Neurodegenerative Disorder Therapeutics Market?

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurodegenerative Disorder Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company

Neurology Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report

Interventional Neurology Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Neurosurgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurosurgery-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

May 1, 2026
Alzheimer’s disease prevalence is fueling the Leqembi Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Leqembi Market Expected To Change Between 2026 And 2030?

Historical expansion was spurred by the rising incidence of Alzheimer’s disease, coupled with developments in monoclonal antibody research, heightened understanding of the importance of early diagnosis, the broadening of neurology specialty care, and regulatory clearances for targeted therapies.

Anticipated growth during the forecast period is expected to arise from increased investments in neurodegenerative disease research, the rising embrace of early diagnostic instruments, the expansion of personalized Alzheimer’s treatment protocols, a growing concentration on decelerating disease progression, and enhanced payer coverage for innovative therapies. Concurrently, prominent trends anticipated in the forecast period include the increasing adoption of therapies targeting amyloid, a heightened focus on early-stage Alzheimer’s interventions, an escalating demand for disease-modifying neurodegenerative treatments, the broadened application of biomarker-guided patient selection, and improved monitoring of cognitive outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

Which Major Factors Are Driving The Expansion Of The Leqembi Market?

The rising incidence of Alzheimer’s disease is significantly influencing the leqembi market. Alzheimer’s is a progressive neurodegenerative condition impacting memory, cognitive abilities, and behavior, thereby disrupting daily life. This intricate disorder arises from a combination of genetic, lifestyle, and environmental factors. Leqembi works by diminishing beta-amyloid plaques in the brain, thereby assisting in mitigating cognitive deterioration in individuals with early Alzheimer’s disease through plaque targeting and the preservation of memory and cognitive functions. For example, data from September 2024 by the European Brain Council, an international health organization based in Belgium, indicates that around 7 million people in Europe currently suffer from Alzheimer’s disease, a figure projected to reach 14 million by 2030, primarily due to an aging demographic, thus posing a substantial global public health issue. Consequently, the increasing occurrence of Alzheimer’s disease is stimulating expansion within the leqembi market. A key company operating in the leqembi market is concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to lessen how often individuals with Alzheimer’s disease need administration. An intravenous (IV) maintenance dosing regimen entails delivering a steady or repeated dose of medication directly into the bloodstream to maintain therapeutic concentrations for an extended period. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical company based in Japan, and Biogen Inc., a biotechnology company from the US, revealed that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing approach. This therapy specifically targets harmful amyloid proteins, particularly protofibrils, which are thought to play a role in the cognitive decline associated with Alzheimer’s disease (AD). LEQEMBI has demonstrated both clinical and biomarker advantages, including prolonging treatment effectiveness, potentially decreasing neuronal damage, and enhancing patient outcomes over the long term.

How Is The Leqembi Market Structured Across Different Segments?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Which Major Players Dominate The Leqembi Market?

Major companies operating in the leqembi market are Eisai Co. Ltd.

Read the full leqembi market report here:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Region Currently Holds The Largest Share Of The Leqembi Market?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqembi Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20142&type=smp

Browse Through More Reports Similar to the Global Leqembi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 26, 2026
Alzheimer’s disease prevalence is fueling the Leqembi Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Leqembi Market Expected To Change Between 2026 And 2030?

Historical expansion was spurred by the rising incidence of Alzheimer’s disease, coupled with developments in monoclonal antibody research, heightened understanding of the importance of early diagnosis, the broadening of neurology specialty care, and regulatory clearances for targeted therapies.

Anticipated growth during the forecast period is expected to arise from increased investments in neurodegenerative disease research, the rising embrace of early diagnostic instruments, the expansion of personalized Alzheimer’s treatment protocols, a growing concentration on decelerating disease progression, and enhanced payer coverage for innovative therapies. Concurrently, prominent trends anticipated in the forecast period include the increasing adoption of therapies targeting amyloid, a heightened focus on early-stage Alzheimer’s interventions, an escalating demand for disease-modifying neurodegenerative treatments, the broadened application of biomarker-guided patient selection, and improved monitoring of cognitive outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20142&type=smp

Which Major Factors Are Driving The Expansion Of The Leqembi Market?

The rising incidence of Alzheimer’s disease is significantly influencing the leqembi market. Alzheimer’s is a progressive neurodegenerative condition impacting memory, cognitive abilities, and behavior, thereby disrupting daily life. This intricate disorder arises from a combination of genetic, lifestyle, and environmental factors. Leqembi works by diminishing beta-amyloid plaques in the brain, thereby assisting in mitigating cognitive deterioration in individuals with early Alzheimer’s disease through plaque targeting and the preservation of memory and cognitive functions. For example, data from September 2024 by the European Brain Council, an international health organization based in Belgium, indicates that around 7 million people in Europe currently suffer from Alzheimer’s disease, a figure projected to reach 14 million by 2030, primarily due to an aging demographic, thus posing a substantial global public health issue. Consequently, the increasing occurrence of Alzheimer’s disease is stimulating expansion within the leqembi market. A key company operating in the leqembi market is concentrating on creating sophisticated intravenous (IV) maintenance dosing formulations to lessen how often individuals with Alzheimer’s disease need administration. An intravenous (IV) maintenance dosing regimen entails delivering a steady or repeated dose of medication directly into the bloodstream to maintain therapeutic concentrations for an extended period. For example, in June 2024, Eisai Co., Ltd., a pharmaceutical company based in Japan, and Biogen Inc., a biotechnology company from the US, revealed that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing approach. This therapy specifically targets harmful amyloid proteins, particularly protofibrils, which are thought to play a role in the cognitive decline associated with Alzheimer’s disease (AD). LEQEMBI has demonstrated both clinical and biomarker advantages, including prolonging treatment effectiveness, potentially decreasing neuronal damage, and enhancing patient outcomes over the long term.

How Is The Leqembi Market Structured Across Different Segments?

The leqembi market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions

2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

Which Major Players Dominate The Leqembi Market?

Major companies operating in the leqembi market are Eisai Co. Ltd.

Read the full leqembi market report here:

https://www.thebusinessresearchcompany.com/report/leqembi-global-market-report

Which Region Currently Holds The Largest Share Of The Leqembi Market?

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqembi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Leqembi Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20142&type=smp

Browse Through More Reports Similar to the Global Leqembi Market 2026, By The Business Research Company

Inductor Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/inductor-market-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 26, 2026